Antiviral Activity of Native and Modified Fucoidans from Brown Algae Fucus evanescens in vitro and in vivo: A Comparative Analysis

Science Press Release Distribution Services

Antiviral Activity of Native and Modified Fucoidans from Brown Algae Fucus evanescens in vitro and in vivo: A Comparative Analysis

June 24, 2021 Microbiology and Biotechnology 0

Fucoidans from brown algae were depolymerized enzymatically, allowing the production of standardized derivatives with various biological activities. The purpose of this study was to compare the antiviral activities of native (FeF) and enzyme-modified (FeHMP) fucoidans from F. evanescens. Using methylthiazolyltetrazolium bromide (MTT) and cytopathic effect (CPE) reduction assays, the cytotoxicity and antiviral activities of the FeF and FeHMP against herpes viruses (HSV-1, HSV-2), enterovirus (ECHO-1), and human immunodeficiency virus (HIV-1) in Vero and human MT-4 cell lines were investigated. Fucoidans were tested in vivo in an outbred mouse model of vaginitis caused by In vitro, they induced CPE and were more effective against HSV. When FeF or FeHMP were added before virus infection or at the early stages of the HSV-2 lifecycle, they exhibited antiviral activity against HSV-2 with a selective index (SI) > 40 and antiviral activity against HSV-2 with a SI 20. In vivo studies also revealed that after intraperitoneal administration (10 mg/kg), both FeF and FeHMP protected mice from lethal intravaginal HSV-2 infection to roughly the same extent (44–56 percent). As a result, FeF and FeHMP have comparable potency against a variety of DNA and RNA viruses, allowing us to consider the investigated fucoidans as promising broad-spectrum antivirals. According to the findings, standardized fucoidan with a regular structure as Native fucoidan has comparable antiviral activity against a variety of DNA- and RNA-containing viruses associated with severe human pathology.

Author (S) Details

Natalya V. Krylova
G.P. Somov Institute of Epidemiology and Microbiology, 690087 Vladivostok, Russia.

Svetlana P. Ermakova
G.B. Elyakov Pacific Institute of Bioorganic Chemistry, 690022 Vladivostok, Russia.

Vyacheslav F. Lavrov
I.I. Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia.

Irina A. Leneva
I.I. Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia.

Galina G. Kompanets
G.P. Somov Institute of Epidemiology and Microbiology, 690087 Vladivostok, Russia.

Olga V. Iunikhina
G.P. Somov Institute of Epidemiology and Microbiology, 690087 Vladivostok, Russia.

Marina N. Nosik
I.I. Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia.

Linna K. Ebralidze
I.I. Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia.

Irina N. Falynskova
I.I. Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia.

Artem S. Silchenko
G.B. Elyakov Pacific Institute of Bioorganic Chemistry, 690022 Vladivostok, Russia.

Tatyana S. Zaporozhets
G.P. Somov Institute of Epidemiology and Microbiology, 690087 Vladivostok, Russia.

View Book :- https://stm.bookpi.org/RPMB-V6/article/view/1675

 

Leave a Reply

Your email address will not be published. Required fields are marked *